Acumen Pharmaceuticals, Inc. (ABOS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Acumen Pharma (ABOS) Q1 2026: $35.75M EBD Funding Extends Runway to 2027, Pipeline Optionality Builds
  May 12, 2026
• Acumen (ABOS) Q4 2025: EBD Platform Spurs $36M Raise as Brain Penetration Hits 40X in Preclinical
  March 26, 2026
• Acumen (ABOS) Q3 2025: $136M Cash Extends Runway Into 2027 as Phase 2 Alzheimer's Trial Progresses
  November 12, 2025
• Acumen Pharmaceuticals (ABOS) Q2 2025: $166M Cash Runway Extends to 2027 as EBD Pipeline Advances
  August 12, 2025
• Acumen Pharmaceuticals (ABOS) Q3 2024: Altitude AD Enrollment Surges 75 Sites, Accelerating Phase 2 Momentum
  November 12, 2024
• Acumen Pharmaceuticals (ABOS) Q2 2024: ALTITUDE-AD Enrollment Surges Past Projections, Extending Runway for Next-Gen Alzheimer’s Antibody
  August 13, 2024
• Acumen Pharmaceuticals (ABOS) Q1 2024: R&D Spend Rises 54% as Altitude AD Phase 2 Launches
  May 14, 2024
• Acumen (ABOS) Q4 2023: $306M Cash Extends Runway, Phase 2 Altitude-AD Launches on Biomarker Momentum
  March 26, 2024
• Acumen (ABOS) Q3 2023: $50M Credit Bolsters Subcutaneous Alzheimer’s Antibody Push
  November 13, 2023

Browse all companies